Search the Newsreel

Pfizer, Inc. (PFE) Stock Price, News, Quote & History

This page provides a comprehensive overview of Pfizer, Inc. (PFE) stock information, including its real-time price, recent news, and performance data. The stock closed at $27.05, up 1.08%, with overnight trading activity showing a slight dip to $26.97. Recent news highlights Pfizer's Q2 earnings, …

Pfizer Inc (PFE-N) Press Releases

This page aggregates recent news and analyst opinions concerning Pfizer Inc. (PFE-N). It covers topics such as Pfizer's earnings, dividend outlook, advancements in COVID-19 booster strategies with BioNTech, and development of new weight-loss drugs. Various financial analysts and news outlets provide insights into the …

Pfizer Inc. stock outperforms competitors on strong trading day

Pfizer Inc. (PFE) shares rose 1.08% to $27.05 on Monday, extending its winning streak to seven consecutive days, despite a generally downbeat trading session for the broader market. The S&P 500 Index fell 0.06%, and the Dow Jones Industrial Average dropped 0.11%, highlighting Pfizer's …

Dudley & Shanley Inc. Makes New $3.97 Million Investment in Pfizer Inc. $PFE

Dudley & Shanley Inc. has acquired a new stake in Pfizer Inc. worth $3.97 million, purchasing 165,000 shares during the second quarter. This comes as Pfizer exceeded Q2 earnings expectations with adjusted EPS of $0.77 and revenue of $15.03 billion, while also issuing fiscal …

Direct Relief and The Pfizer Foundation Expand Support for Community Health Centers on the Front Lines of Infectious Disease Care

Direct Relief and The Pfizer Foundation have announced the third cohort of their Innovation Awards in Community Health, committing $4.5 million in grants over two years to 16 U.S. safety-net community health organizations. This initiative, now in its fifth year, supports efforts to strengthen …

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer's stock rose almost 7% after its Q2 2026 results, beating earnings and revenue estimates, driven by non-COVID products despite declining COVID vaccine and treatment sales. The company raised the lower end of its 2026 revenue guidance but faces challenges from declining COVID product …

Pfizer explores localisation, supply-chain and healthcare partnerships across Middle East, Africa

Pfizer is actively seeking manufacturing, technology transfer, research, and capability-building partnerships across the Middle East and Africa. This initiative responds to the region's growing demand for drug security and innovative therapies, driven by demographic growth and increased healthcare investment. The company aims to strengthen …

Biotechnology Stocks To Watch As Investors Look Past Pfizer’s Covid Revenue Drop

Pfizer $44M settlement: How to know if you are included

Pfizer will pay $44 million to settle a class-action lawsuit concerning its smoking-cessation drug Chantix, which allegedly contained an undisclosed nitrosamine. The settlement covers U.S. individuals and third-party payors who purchased Chantix between September 29, 2015, and September 17, 2021. Claimants must file by …

Insider trades: Microsoft, Meta, Pfizer among notable names

[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …

Insider trades: Microsoft, Meta, Pfizer among notable names (PFE:NYSE)

This article reports on notable insider trading activity that occurred between August 3 and August 7, 2026, involving several major companies. Executives at Microsoft and Meta divested portions of their holdings, while insider purchases were observed in companies like Pfizer, Taiwan Semiconductor, and Tilray …

Pfizer, Inc. (PFE) Stock Forecasts

Argus Senior Analyst David H. Toung has published a report on Pfizer Inc. (PFE), highlighting strong growth from the company's non-COVID products. The report provides a summary of Pfizer's position as a leading developer of pharmaceuticals and biotech drugs, including oncology, immunology, rare disease …

Pfizer Inc (PFE) Aktienanalyse & Prognose

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Análise e Previsão das Ações da Pfizer Inc (PFE)

Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP significantly reduced its stake in Pfizer Inc. by 37.7% in the second quarter of 2026, selling over 510,000 shares. Despite this, Pfizer reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue, and raised the low end of …

Pfizer Inc (PFE) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

How Pfizer Thinks About AI

Albert Bourla, CEO of Pfizer, outlines the company's ambition to be the most AI-forward in the pharmaceutical industry. He details three key strategies: structuring 177 years of data, federating AI across the organization to empower employees, and investing in AI fluency for all colleagues. …

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

Company Logo Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding …

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Pfizer, Merck, and Amgen are expanding their cancer portfolios, leading to increased speculation about smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX) being potential acquisition targets. Pfizer's Seagen portfolio and Padcev, Merck's sac-TMT, and Amgen's T-cell engagers and Imdelltra are key …

Warum die Pfizer-Aktie (PFE) trotz eines Nettoverlusts im zweiten Quartal um 5,2 % gestiegen ist, nachdem das Unternehmen seine Prognose für 2026 angehoben hat

Why Pfizer (PFE) Is Up 5.2% After Raising 2026 Guidance Despite a Q2 Net Loss

Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Novavax Inc (NASDAQ:NVAX) has secured licensing or material transfer agreements with 4 of the TOP10 …

Pfizer Inc Earnings Call Signals Cautious Optimism

Pfizer Inc.'s Q2 earnings call revealed cautious optimism, with core revenues and adjusted EPS surpassing expectations, leading to raised full-year revenue guidance. The company demonstrated strong performance in oncology and neuroscience, alongside significant R&D activity, despite setbacks from a clinical trial miss, weaker COVID …

Pfizer shares rise after strong Q2 earnings des...

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)

This article provides analyst ratings and price targets for three healthcare companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE), and Allogene Therapeutics (ALLO). Citi analyst Geoff Meacham maintained a Hold rating on Pfizer, while Citi analyst Yigal Nochomovitz maintained a Buy rating on Ultragenyx Pharmaceutical. William …

Pfizer (PFE) Stock Trades At A Premium Despite Its 27% Five Year Fall

Pfizer’s Q2 Earnings Beat by Double Digits. A $4.3 Billion Writedown Stole the Headline.

Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year …

Pfizer Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:PFE) 2026-08-04

This article provides access to the slide deck published by Pfizer Inc. in conjunction with their Q2 2026 earnings call. The report highlights that Pfizer's EPS of $0.77 beat expectations by $0.09, and revenue of $15.03 billion, up 2.60% year-over-year, beat by $645.82 million.

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

This article first appeared on GuruFocus. Pfizer (NYSE:PFE), the pharmaceutical giant behind some of the world's biggest blockbuster drugs, edged about 0.5% lower in Tuesday's early trading despite delivering another earnings beat and raising its revenue outlook. The market appeared unconvinced that better quarterly …

Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts

Pfizer Inc. PFE used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity. Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call …

Company News for Aug 5, 2026

Allison Transmission Holdings Inc.'s (ALSN) shares surged 5.4% after reporting second-quarter 2026 adjusted earnings of $2.73 per share, surpassing the Zacks Consensus Estimate of $2.60 per share. Shares of The Clorox Co. (CLX) climbed 6.5% after posting fourth-quarter fiscal 2026 adjusted earnings of $1.66 …

Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer (PFE) Stock Faces Pipeline Doubts After Higher Revenue Outlook

Pfizer Earnings Reveal New Engine Beyond Covid

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) delivered stronger-than-expected second-quarter results as Specialty Care and newer acquired medicines offset continued weakness across Primary Care, reinforcing the company's transition away from pandemic-era products. The split matters because Pfizer's recovery increasingly depends on specialty drugs …